We’re on a mission to address the needs of millions of patients suffering from mental health disorders by re-thinking what’s possible in CNS drug development
Carmel, IN
Joined August 2022
- Tweets17
- Following44
- Followers33
- Likes17
Check out our spotlight piece in Drug Discovery World's summer issue! Co-founder Dr. Anantha Shekhar shares perspectives on the challenges and opportunities for neuroplastogen therapies in #mentalhealth
The Summer issue of Drug Discovery World (DDW) is out now!
Read the digital version here:
ddw-online.com/ddw-summer-is…
#DrugDiscovery
Gate Neurosciences retweeted
.@GateNeuro and @biosignals illuminate depression biomarkers with EEG bioworld.com/articles/705051 #biotech #pharma
Happy to announce our collab with @biosignals to advance #precisionmedicine in neuropsychiatry! We will be including their Dreem 3S headband in our upcoming zelquistinel Phase 2 trial in MDD to explore novel EEG biomarker endpoints
Excited to partner with @GateNeuro for a Phase 2 trial on zelquistinel to treat major depressive disorder! 🚀 Leveraging FDA-cleared Dreem 3S headband & our AI Analytics, we're bringing precision to psychiatry with novel EEG biomarkers and sleep endpoints!
businesswire.com/news/home/2…
Gate Neurosciences retweeted
Excited to partner with @GateNeuro for a Phase 2 trial on zelquistinel to treat major depressive disorder! 🚀 Leveraging FDA-cleared Dreem 3S headband & our AI Analytics, we're bringing precision to psychiatry with novel EEG biomarkers and sleep endpoints!
businesswire.com/news/home/2…
Gate Neurosciences retweeted
Gate Neurosciences Collaborates with Beacon Biosignals to Leverage EEG Biomarkers in Major Depressive Disorder. Learn more: ow.ly/CqVz50Qu1vO
Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs:
mdpi.com/1424-8247/16/11/157…
"Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!
Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism
A new generation of psychedelics could offer mental-health benefits to a huge number of people.
The secret: no trips, highs, or hallucinations, @raf_ideas writes: theatlantic.com/health/archi…
We're excited to share the latest clinical trial results for our rapid-acting IV antidepressant, apimostinel. These new qEEG #biomarker data reflect NMDAR activation and enhanced synaptic function, to help guide future clinical trials. Link: lnkd.in/eRjJauNj
#mentalhealth
Great to see coverage in @WIRED on the link between #neuroplasticity and #depression.
Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days.
#mentalhealth
A clinical trial reveals the first evidence of how the brain restructures physically in the first month on SSRIs—and the link between neuroplasticity and depression. wired.trib.al/hAlIkic
Gate Neurosciences retweeted
In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology.
They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: drugdiscoverytrends.com/gate…
As part of our commitment to #mentalhealth innovation, we recently expanded our research facilities in Evanston! This renewed effort includes advancing translational EEG biomarkers supporting our '-stinel' programs that enhance synaptic function.
businesswire.com/news/home/2…
Gate Neurosciences retweeted
I will be in Boston next week at the Cowen Healthcare Conference Mar 6-8. Looking forward to seeing everyone. We are making great progress at Gate Neuro and have news forthcoming about our expanded R&D and results from our clinical biomarker study. #neuroscience #mentalheath
Gate Neurosciences retweeted
The underlying mechanism of ketamine in depression requires downstream NMDAR-activation. New publication from Todd Gould (gouldlab.org/)
jneurosci.org/content/early/…
Gate Neuro was recently featured in @PsychTimes ! Co-founder Dr. Anantha Shekhar discusses our ongoing biomarker study with apimostinel, a rapid-acting and safe NMDAR modulator in development for acute depressive disorders. #mentalhealth #precisionmedicine
bit.ly/3XtKmi7
This week we announced dosing the first patient cohort in a translational EEG biomarker study of apimostinel. Press release: businesswire.com/news/home/2…
Gate is committed to #mentalhealth innovation. This morning we announced a publication on the novel NMDA mechanism underlying rapid, durable & safe activity with our lead oral program in Phase 2: bit.ly/3fyrGg4
Link to paper in IJNP: bit.ly/3UQqNzg
#biotech
We are excited to officially emerge from stealth! A big thanks to our team, investors, and @abbvie and @LillyPad for their partnership in assembling our next-generation CNS portfolio. Learn more about us here: bit.ly/3Kdr5vk
#neuroscience #mentalhealth #biotech
